Last updated today
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big pharmas such as Novaris AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010 decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.
Last updated today
Coming soon.
No recent security news.
More security reports
Cybersecurity & Risk Management Library
The ultimate guide to attack surface and third-party risk management – actionable advice for security teams, managers, and executives.
Breaches
Security research and global news about data breaches.
Explore resources
Third-party risk management
Articles, news, and research on third-party risk management.
Explore resources
Attack Surface Management
Articles, news, and research on attack surface management.
Explore resources
Cybersecurity
Articles, news, and research on cybersecurity.
Explore resources
Leader in Third Party & Supplier Risk Management Software
See how UpGuard shapes up against other platforms in the market.
"This is some text inside of a div block."
Free instant security score
How secure is your organization?
Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
- Instant insights you can act on immediately
- Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Want a full vendor security report for this company?
Start your free trial and unlock real-time insights to identify and assess vendor risks.